Skip to content

Bacteriophage therapy for multi-drug resistance bacterial infection

Bacteriophage therapy for multi-drug resistance bacterial infection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062708
Enrollment
Unknown
Registered
2022-08-16
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multi-drug resistance bacterial infection

Interventions

Bacteriophage therapy Group:Bacteriophage
Bacteriophage therapy Group:antibiotics

Sponsors

Second Affiliated Hospital of Southern University of Science and Technology(the Third People's Hospital of Shenzhen)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. 1-90 years old patients with multi-drug resistant bacterial infection (based on the drug susceptibility test results of our hospital or other first-class hospitals in Grade 3); 2. The pathogen infected by the patient should meet one of the following conditions: (1) Pathogens are fully resistant to antibiotics; (2) Pathogens are resistant to key antibiotics; (3) Pathogens are sensitive to critical antibiotics in vitro, but this antibiotic treatment is ineffective or not significantly effective in the body. (4) Pathogenic bacteria that are limited in their use of key sensitive antibiotics (patients with organ function impairment or allergy to this antibiotic) 3. Ability to screen for at least one or more phages matching the resistant organism; 4. the ability to administer the drug by topical application, focal spraying of infection, nebulized inhalation, perfusion, local injection or catheter; 5. the subject and family (or guardian) have fully read, understood and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Bacterial infections can be effectively controlled by antibiotic therapy; 2. here was no effective route of administration other than Intravenous; 3. Over the medical service capacity of the hospital; 4. Patients are unsuitable to participate in this studyarare by the investigator.

Design outcomes

Primary

MeasureTime frame
sputum culture;urine culture;fecal culture;Prostatic fluid;Pleural effusion;Puncture fluid;Secretion;

Countries

China

Contacts

Public ContactHongzhou Lu
luhongzhou@fudan.edu.cn+86 755 61222333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026